{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:42:45Z","timestamp":1793292165507,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>This head-to-head comparison study was designed to investigate the radiotracer uptake and clinical feasibility of using <jats:sup>68<\/jats:sup>Ga-LNC1007, to detect the primary and metastatic lesions in patients with various types of cancer, and to compare the results with those of 2-<jats:sup>18<\/jats:sup>F-FDG PET\/CT and <jats:sup>68<\/jats:sup>Ga-FAPI-02 PET\/CT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Sixty-one patients with 10 different kinds of cancers were enrolled in this study. Among them, 50 patients underwent paired <jats:sup>68<\/jats:sup>Ga-LNC1007 and 2-<jats:sup>18<\/jats:sup>F-FDG PET\/CT, and the other 11 patients underwent paired <jats:sup>68<\/jats:sup>Ga-LNC1007 and <jats:sup>68<\/jats:sup>Ga-FAPI-02 PET\/CT. The final diagnosis was based on histopathological results and diagnostic radiology. Immunohistochemistry for FAP and integrin \u03b1<jats:sub>v<\/jats:sub>\u03b2<jats:sub>3<\/jats:sub> was performed in 24 primary tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga-LNC1007 PET\/CT detected all 55 primary tumors, whereas 2-<jats:sup>18<\/jats:sup>F-FDG PET\/CT was visually positive for 45 primary tumors (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002). Furthermore, subgroup analysis showed that <jats:sup>68<\/jats:sup>Ga-LNC1007 PET\/CT was superior to 2-<jats:sup>18<\/jats:sup>F-FDG PET\/CT in diagnosing renal cell carcinomas and hepatocellular carcinomas. For metastatic tumors, <jats:sup>68<\/jats:sup>Ga-LNC1007 PET\/CT revealed more PET-positive lesions and higher SUV<jats:sub>max<\/jats:sub> for skeletal metastases and peritoneal metastases compared with 2-<jats:sup>18<\/jats:sup>F-FDG. The SUV<jats:sub>max<\/jats:sub> and tumor-to-background ratio of primary tumors on <jats:sup>68<\/jats:sup>Ga-LNC1007 PET\/CT were much higher than those on <jats:sup>68<\/jats:sup>Ga-FAPI-02 PET\/CT, the same was also observed for metastatic tumors. Immunohistochemical results showed that the SUV<jats:sub>mean<\/jats:sub> quantified from <jats:sup>68<\/jats:sup>Ga-LNC1007 PET was correlated with FAP expression level (<jats:italic toggle=\"yes\">r<\/jats:italic> = 0.564, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.005).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga-LNC1007 is a promising new diagnostic PET tracer for imaging of various kinds of malignant lesions. It may be a better alternative to 2-<jats:sup>18<\/jats:sup>F-FDG for diagnosing renal cell carcinoma, hepatocellular carcinoma, skeletal metastases, and peritoneal metastases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004820","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T16:00:44Z","timestamp":1694188844000},"page":"861-868","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG\/68Ga-FAPI-02 PET\/CT in Patients With Various Cancers"],"prefix":"10.1097","volume":"48","author":[{"given":"Jie","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Wen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics and Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Nuclear Science and Technology, Harbin Engineering University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhide","family":"Guo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics and Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13550-022-00922-x","article-title":"A pilot study of 68Ga-PSMA-617 PET\/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma","volume":"12","year":"2022","journal-title":"EJNMMI Res"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s00259-007-0692-y","article-title":"(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression","volume":"35","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","first-page":"1172","article-title":"A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression","volume":"47","year":"2006","journal-title":"J Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2967\/jnumed.115.160648","article-title":"68Ga-NOTA-PRGD2 PET\/CT for integrin imaging in patients with lung cancer","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s00259-015-3118-2","article-title":"(18)F-Alfatide II PET\/CT in healthy human volunteers and patients with brain metastases","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1007\/s00259-022-05799-5","article-title":"[68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET\/CT","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.7150\/thno.79144","article-title":"Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD","volume":"12","year":"2022","journal-title":"Theranostics"},{"key":"bib11-20250621","article-title":"Clinical evaluation of 68Ga-FAPI-RGD for imaging of fibroblast activation protein and integrin \u03b1v\u03b23 in various cancer types","year":"2023","journal-title":"J Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1007\/s00259-017-3696-2","article-title":"Inter-heterogeneity and intra-heterogeneity of \u03b1v\u03b23 in non-small cell lung cancer and small cell lung cancer patients as revealed by 68Ga-RGD2 PET imaging","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00259-021-05638-z","article-title":"[18F]AlF-NOTA-FAPI-04 PET\/CT uptake in metastatic lesions on PET\/CT imaging might distinguish different pathological types of lung cancer","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20250621","first-page":"201","article-title":"The place of FDG PET\/CT in renal cell carcinoma: value and limitations","volume":"6","year":"2016","journal-title":"Front Oncol"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.2967\/jnumed.108.055087","article-title":"A prospective evaluation of 18F-FDG and 11C-acetate PET\/CT for detection of primary and metastatic hepatocellular carcinoma","volume":"49","year":"2008","journal-title":"J Nucl Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.3390\/cancers12113393","article-title":"Altered tissue and plasma levels of fibroblast activation protein-\u03b1 (FAP) in renal tumours","volume":"12","year":"2020","journal-title":"Cancers (Basel)"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","article-title":"Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:00:50Z","timestamp":1750532450000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004820","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,2]]}}}